Compare Stocks: PVLA, SYRE, PCVX, and IMVT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IMVT Immunovant	$41.82	$38.19	$14.47 ▼ $42.92	$8.64B	0.77	1.03 million shs	722,453 shs
PCVX Vaxcyte	$58.07	$54.95	$29.87 ▼ $65.00	$8.64B	1.23	961,014 shs	656,559 shs
PVLA Palvella Therapeutics	$156.13	$138.12	$44.24 ▼ $161.38	$2.25B	-0.17	194,162 shs	109,815 shs
SYRE Spyre Therapeutics	$103.63	$94.21	$14.51 ▼ $108.14	$9.11B	3.03	797,075 shs	559,474 shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IMVT Immunovant	0.00%	+4.68%	+3.87%	+57.63%	+174.77%
PCVX Vaxcyte	0.00%	0.00%	+3.33%	+19.88%	+77.58%
PVLA Palvella Therapeutics	0.00%	-1.04%	-0.71%	+48.62%	+230.08%
SYRE Spyre Therapeutics	0.00%	-1.22%	+3.39%	+47.87%	+511.39%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IMVT Immunovant	$41.82	$38.19	$14.47 ▼ $42.92	$8.64B	0.77	1.03 million shs	722,453 shs
PCVX Vaxcyte	$58.07	$54.95	$29.87 ▼ $65.00	$8.64B	1.23	961,014 shs	656,559 shs
PVLA Palvella Therapeutics	$156.13	$138.12	$44.24 ▼ $161.38	$2.25B	-0.17	194,162 shs	109,815 shs
SYRE Spyre Therapeutics	$103.63	$94.21	$14.51 ▼ $108.14	$9.11B	3.03	797,075 shs	559,474 shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IMVT Immunovant	0.00%	+4.68%	+3.87%	+57.63%	+174.77%
PCVX Vaxcyte	0.00%	0.00%	+3.33%	+19.88%	+77.58%
PVLA Palvella Therapeutics	0.00%	-1.04%	-0.71%	+48.62%	+230.08%
SYRE Spyre Therapeutics	0.00%	-1.22%	+3.39%	+47.87%	+511.39%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IMVT Immunovant	2.50	Moderate Buy	$44.00	5.21% Upside
PCVX Vaxcyte	2.50	Moderate Buy	$86.00	48.10% Upside
PVLA Palvella Therapeutics	3.00	Buy	$209.14	33.95% Upside
SYRE Spyre Therapeutics	2.87	Moderate Buy	$111.69	7.78% Upside

Current Analyst Ratings Breakdown

Latest PVLA, SYRE, PCVX, and IMVT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2026	PCVX Vaxcyte	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/11/2026	SYRE Spyre Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$112.00 ➝ $132.00
8/5/2026	PVLA Palvella Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$207.00
8/5/2026	SYRE Spyre Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$120.00
8/5/2026	PVLA Palvella Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$232.00
8/5/2026	SYRE Spyre Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$90.00 ➝ $115.00
8/5/2026	SYRE Spyre Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$100.00 ➝ $130.00
8/5/2026	SYRE Spyre Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$115.00 ➝ $130.00
8/4/2026	IMVT Immunovant	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$47.00 ➝ $50.00
7/29/2026	IMVT Immunovant	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
7/28/2026	PVLA Palvella Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 8/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IMVT Immunovant	N/A	N/A	N/A	N/A	$4.19 per share	N/A
PCVX Vaxcyte	N/A	N/A	N/A	N/A	$20.51 per share	N/A
PVLA Palvella Therapeutics	$42.81M	52.55	N/A	N/A	$2.36 per share	66.16
SYRE Spyre Therapeutics	$890K	10,239.58	N/A	N/A	$7.21 per share	14.37

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IMVT Immunovant	-$505.61M	-$2.82	N/A	N/A	N/A	N/A	-69.59%	-62.49%	N/A
PCVX Vaxcyte	-$766.63M	-$7.63	N/A	N/A	N/A	N/A	-37.56%	-33.62%	11/3/2026 (Estimated)
PVLA Palvella Therapeutics	-$41.72M	-$4.83	N/A	N/A	N/A	N/A	-47.84%	-38.33%	N/A
SYRE Spyre Therapeutics	-$155.20M	-$1.95	N/A	N/A	N/A	N/A	-30.74%	-22.23%	11/3/2026 (Estimated)

Latest PVLA, SYRE, PCVX, and IMVT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q1 2027	IMVT Immunovant	-$0.6289	-$0.75	-$0.1211	-$0.75	$7.10 million	$7.10 million
8/5/2026	Q2 2026	PCVX Vaxcyte	-$2.06	-$1.97	+$0.09	-$1.97	$12.50 million	N/A
8/4/2026	Q2 2026	PVLA Palvella Therapeutics	-$1.17	-$1.52	-$0.35	-$1.52	N/A	N/A
8/4/2026	Q2 2026	SYRE Spyre Therapeutics	-$0.7589	-$0.36	+$0.3989	-$0.36	N/A	N/A
5/20/2026	Q4 2026	IMVT Immunovant	-$0.60	-$0.73	-$0.13	-$0.73	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
IMVT Immunovant	N/A	N/A	N/A	N/A	N/A
PCVX Vaxcyte	N/A	N/A	N/A	N/A	N/A
PVLA Palvella Therapeutics	N/A	N/A	N/A	N/A	N/A
SYRE Spyre Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IMVT Immunovant	N/A	7.27	7.27
PCVX Vaxcyte	N/A	5.72	5.72
PVLA Palvella Therapeutics	N/A	21.18	21.18
SYRE Spyre Therapeutics	N/A	18.53	18.53

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IMVT Immunovant	47.08%
PCVX Vaxcyte	96.78%
PVLA Palvella Therapeutics	40.11%
SYRE Spyre Therapeutics	80.39%

Insider Ownership

Company	Insider Ownership
IMVT Immunovant	1.90%
PCVX Vaxcyte	3.30%
PVLA Palvella Therapeutics	17.20%
SYRE Spyre Therapeutics	15.69%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IMVT Immunovant	120	206.55 million	202.63 million	Optionable
PCVX Vaxcyte	160	148.80 million	143.89 million	Optionable
PVLA Palvella Therapeutics	N/A	14.41 million	11.93 million	N/A
SYRE Spyre Therapeutics	73	87.94 million	74.14 million	Optionable

PVLA, SYRE, PCVX, and IMVT Headlines

Recent News About These Companies

Spyre Therapeutics (NASDAQ:SYRE) Downgraded to Sell Rating by Wall Street Zen

August 16 at 1:13 AM | americanbankingnews.com

Wall Street Zen Downgrades Spyre Therapeutics (NASDAQ:SYRE) to Sell

August 16 at 1:11 AM | marketbeat.com

Wedbush Keeps Their Buy Rating on Spyre Therapeutics (SYRE)

August 14 at 9:42 PM | theglobeandmail.com

Dimensional Fund Advisors LP Sells 29,593 Shares of Spyre Therapeutics, Inc. $SYRE

August 14 at 3:43 AM | marketbeat.com

BTIG Research Increases Spyre Therapeutics (NASDAQ:SYRE) Price Target to $132.00

August 13, 2026 | americanbankingnews.com

Spyre Therapeutics Launches Program, Mid-Stage Trial for Drug Combination to Treat Hidradenitis Suppurativa

August 11, 2026 | finance.yahoo.com

Spyre Therapeutics (NASDAQ:SYRE) Stock Price Expected to Rise, BTIG Research Analyst Says

August 11, 2026 | marketbeat.com

Spyre Therapeutics, Inc. $SYRE Shares Bought by Bank of America Corp DE

August 11, 2026 | marketbeat.com

Spyre Therapeutics (NASDAQ:SYRE) Director Sells 18,000 Shares

August 10, 2026 | marketbeat.com

Spyre Therapeutics Announces Launch of SPY772 Program and Initiation of Phase 2 SKYLIGHT Trial in Hidradenitis Suppurativa

August 10, 2026 | markets.businessinsider.com

California State Teachers Retirement System Purchases 11,204 Shares of Spyre Therapeutics, Inc. $SYRE

August 10, 2026 | marketbeat.com

Can Spyre Therapeutics (SYRE) Justify Its Premium After Positive Phase 2 Data?

August 9, 2026 | finance.yahoo.com

Spyre Therapeutics (NASDAQ:SYRE) Upgraded at Wall Street Zen

August 8, 2026 | americanbankingnews.com

Spyre Therapeutics (NASDAQ:SYRE) Stock Rating Upgraded by Wall Street Zen

August 8, 2026 | marketbeat.com

Spyre Therapeutics Announces Grants of Inducement Awards

August 7, 2026 | globenewswire.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Spyre Therapeutics (SYRE), Ultragenyx Pharmaceutical (RARE) and Bruker (BRKR)

August 7, 2026 | theglobeandmail.com

Guggenheim Boosts Spyre Therapeutics (NASDAQ:SYRE) Price Target to $130.00

August 7, 2026 | americanbankingnews.com

Wedbush Forecasts Strong Price Appreciation for Spyre Therapeutics (NASDAQ:SYRE) Stock

August 7, 2026 | americanbankingnews.com

Scott Burrows Sells 7,500 Shares of Spyre Therapeutics (NASDAQ:SYRE) Stock

August 6, 2026 | insidertrades.com

The Manufacturers Life Insurance Company Trims Stock Position in Spyre Therapeutics, Inc. $SYRE

August 6, 2026 | marketbeat.com

Spyre Therapeutics (NASDAQ:SYRE) Hits New 1-Year High Following Earnings Beat

August 6, 2026 | americanbankingnews.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PVLA, SYRE, PCVX, and IMVT Company Descriptions

Immunovant NASDAQ:IMVT

$41.82 0.00 (0.00%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$41.83 +0.01 (+0.02%)

As of 08/14/2026 07:34 PM Eastern

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Vaxcyte NASDAQ:PCVX

$58.07 0.00 (0.00%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$58.07 0.00 (0.00%)

As of 08/14/2026 07:34 PM Eastern

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Palvella Therapeutics NASDAQ:PVLA

$156.13 0.00 (0.00%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$156.24 +0.11 (+0.07%)

As of 08/14/2026 07:34 PM Eastern

Palvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.

Spyre Therapeutics NASDAQ:SYRE

$103.63 0.00 (0.00%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$103.42 -0.20 (-0.20%)

As of 08/14/2026 07:34 PM Eastern

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PVLA, SYRE, PCVX, and IMVT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PVLA, SYRE, PCVX, and IMVT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PVLA, SYRE, PCVX, and IMVT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PVLA, SYRE, PCVX, and IMVT Company Descriptions

Immunovant NASDAQ:IMVT

Vaxcyte NASDAQ:PCVX

Palvella Therapeutics NASDAQ:PVLA

Spyre Therapeutics NASDAQ:SYRE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PVLA, SYRE, PCVX, and IMVT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PVLA, SYRE, PCVX, and IMVT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PVLA, SYRE, PCVX, and IMVT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PVLA, SYRE, PCVX, and IMVT Company Descriptions

Immunovant NASDAQ:IMVT

Vaxcyte NASDAQ:PCVX

Palvella Therapeutics NASDAQ:PVLA

Spyre Therapeutics NASDAQ:SYRE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools